CLSI Publishes New Editions of Antifungal Documents M59, M60, and M61
The Clinical and Laboratory Standards Institute (CLSI) has published three new editions of antifungal testing documents M59, M60, and M61.
M59--Epidemiological Cutoff Values for Antifungal Susceptibility Testing, 3rd Edition provides epidemiological cutoff values developed according to the criteria in the Clinical and Laboratory Standards Institute (CLSI) guideline M57 and generated according to the reference broth dilution methods described in the CLSI standards M27 and M38.
M60--Performance Standards for Antifungal Susceptibility Testing of Yeasts, 2nd Edition provides updated minimal inhibitory concentration, zone diameter, and quality control tables for the Clinical and Laboratory Standards Institute antifungal susceptibility testing documents M27 and M44.
M61--Performance Standards for Antifungal Susceptibility Testing of Filamentous Fungi, 2nd Edition provides minimal inhibitory concentration breakpoints and quality control tables for the Clinical and Laboratory Standards Institute antifungal susceptibility testing documents M38 and M51.
For more information about M59, M60, and M61 contact Patrick McGinn at email@example.com or +1.484.588.5933.
CLSI sets the standard for quality in medical laboratory testing. A not-for-profit membership organization, CLSI brings together the global laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine.
For over 50 years, our members, volunteers, and customers have made CLSI a respected, transformative leader in the development and implementation of medical laboratory testing standards. Through our unified efforts, we will continue to set and uphold the standards that drive quality test results, enhance patient care delivery, and improve health care around the world.
By using CLSI standards, laboratorians can improve process quality, speed the development of standard operating procedures, and implement safer practices with greater ease and efficiency.